Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol

These findings provide unequivocal evidence that the extent of reduction of serum cholesterol achieved by a combination of therapeutic measures, including statins, ezetimibe, lipoprotein apheresis, and evolocumab, is a major determinant of survival in homozygous FH.